CALCIUM MODULATION OF COLON CANCER INTERMEDIATE MARKERS
CALCIUM MODULATION OF COLON CANCER INTERMEDIATE MARKERS
批准号:
3423258
负责人:
PATRICK M. LYNCH
金额:
$3.46万
依托单位国家:
美国
项目类别:
财政年份:
1989
资助国家:
美国
项目状态:
已结题
起止时间:
1989-09-10 至 1990-08-31
中文摘要
点击翻译按钮获取中文摘要
英文摘要
A high risk for colon cancer may correlate positively with the,
proliferative activity or enzymatic activity in colon mucosa as measured
by several assays: tritiated thymidine autoradiography,
bromodeoxyuridine immunoperoiddase, and ornithine decarboxylue activity.
The proliferative activity of colonic crypt cells has been reported to
be suppressed by the administration of oral calcium. Many issues remain
to be explored in determining the precise role of calcium in the
modulation of colonic cell proliferation and the validity of
intermediate markers of proliferation in monitoring this offect.
This study proposes to evaluate four high-risk groups for colorectal
cancer: a) patients with previous sporadic-type colon cancer, b)
patients with a previous colon cancer who are members of a family with
hereditary non-polyposis colon cancer (HNPCC); c) asymptomatic
individuals at 50% risk of developing colon cancer because of a family
history of HNPCC; d) patients with familial polyposis coli (FPC).
Following stratification to one of the risk-groups, subjects are
randomized to receive either oral calcium (2 g/day) or placebo for 12
weeks, followed by a cross over to the altenate regimen for 12 weeks.
Proliferative activity (tritiated thymidine, bromodeoxyuridine labeuing
and omithine decarboxylase activity) are measured on rectal biopsy at
study entry, and after each of the two study periods (ie placebo or
CaCO3). Proliferative and enzymatic activity profiles will be developed
for each high risk group and the degree of modulation by oral calcium
administration determined. It is anticipated that subject enrolled will
be followed prospectively in order to evaluate long-term trends of
labelling activity, calcium modulation, and clinical correlation.
Issues related to long-term cancer control objectives will be
considered. These will include evaluation of subject recruitment, study
compliance and drop-out, as well as overall patient acceptance of study
requirements.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PHASE II CLINICAL TRIAL OF CELECOXIB IN PERSONS WITH GE
-
批准号:6357838
-
项目类别:
-
资助金额:$325.11万
-
财政年份:2000
-
负责人:PATRICK M. LYNCH
-
依托单位:
PHASE II MULTIPLE-DOSE SAFETY & EFFICACY STUDY OF A SELE
-
批准号:2879697
-
项目类别:
-
资助金额:$47.24万
-
财政年份:1997
-
负责人:PATRICK M. LYNCH
-
依托单位:
PHASE II MULTIPLE-DOSE SAFETY & EFFICACY STUDY OF A SELE
-
批准号:6045773
-
项目类别:
-
资助金额:$0.0万
-
财政年份:1997
-
负责人:PATRICK M. LYNCH
-
依托单位:
PHASE II MULTIPLE-DOSE SAFETY & EFFICACY STUDY OF A SELE
-
批准号:2540016
-
项目类别:
-
资助金额:$152.54万
-
财政年份:1997
-
负责人:PATRICK M. LYNCH
-
依托单位:
PHASE II MULTIPLE-DOSE SAFETY & EFFICACY STUDY OF A SELE
-
批准号:6335874
-
项目类别:
-
资助金额:$0.0万
-
财政年份:1997
-
负责人:PATRICK M. LYNCH
-
依托单位:
A THREE ARM PHASE II CHEMOPREVENTION TRIAL IN ADENOMATOUS POLYPOSIS CO-261095040
-
批准号:7329484
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:PATRICK M. LYNCH
-
依托单位:
PHASE II CLINICAL TRIAL OF CELECOXIB IN PERSONS WITH GENOTYPE POSITIV-261005126
-
批准号:6994811
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:PATRICK M. LYNCH
-
依托单位:
PHASE II CLINICAL TRIAL OF CELECOXIB IN PERSONS WITH GENOTYPE POSITIV-261005126
-
批准号:7191425
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:PATRICK M. LYNCH
-
依托单位:
PHASE II CLINICAL TRIAL OF CELECOXIB IN PERSONS WITH GENOTYPE POSITIV-261005126
-
批准号:7329498
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:PATRICK M. LYNCH
-
依托单位:
海外基金